Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios


suck pdf from google scholar
PDF vom PMID32302448  :  Publisher
PDF vom PMID32302448

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome #MMPMID32302448
  • Ranucci M; Ballotta A; Di Dedda U; Bayshnikova E; Dei Poli M; Resta M; Falco M; Albano G; Menicanti L
  • J Thromb Haemost 2020[Jul]; 18 (7): 1747-1751 PMID32302448show ga
  • BACKGROUND: Few observations exist with respect to the pro-coagulant profile of patients with COVID-19 acute respiratory distress syndrome (ARDS). Reports of thromboembolic complications are scarce but suggestive for a clinical relevance of the problem. OBJECTIVES: Prospective observational study aimed to characterize the coagulation profile of COVID-19 ARDS patients with standard and viscoelastic coagulation tests and to evaluate their changes after establishment of an aggressive thromboprophylaxis. METHODS: Sixteen patients with COVID-19 ARDS received a complete coagulation profile at the admission in the intensive care unit. Ten patients were followed in the subsequent 7 days, after increasing the dose of low molecular weight heparin, antithrombin levels correction, and clopidogrel in selected cases. RESULTS: At baseline, the patients showed a pro-coagulant profile characterized by an increased clot strength (CS, median 55 hPa, 95% interquartile range 35-63), platelet contribution to CS (PCS, 43 hPa; interquartile range 24-45), fibrinogen contribution to CS (FCS, 12 hPa; interquartile range 6-13.5) elevated D-dimer levels (5.5 mug/mL, interquartile range 2.5-6.5), and hyperfibrinogenemia (794 mg/dL, interquartile range 583-933). Fibrinogen levels were associated (R(2) = .506, P = .003) with interleukin-6 values. After increasing the thromboprophylaxis, there was a significant (P = .001) time-related decrease of fibrinogen levels, D-dimers (P = .017), CS (P = .013), PCS (P = .035), and FCS (P = .038). CONCLUSION: The pro-coagulant pattern of these patients may justify the clinical reports of thromboembolic complications (pulmonary embolism) during the course of the disease. Further studies are needed to assess the best prophylaxis and treatment of this condition.
  • |*Blood Coagulation/drug effects[MESH]
  • |Aged[MESH]
  • |Anticoagulants/administration & dosage[MESH]
  • |Betacoronavirus/*pathogenicity[MESH]
  • |Biomarkers/blood[MESH]
  • |Blood Coagulation Disorders/*blood/diagnosis/drug therapy/virology[MESH]
  • |Blood Coagulation Tests[MESH]
  • |Coronavirus Infections/*blood/diagnosis/drug therapy/virology[MESH]
  • |Female[MESH]
  • |Fibrinolytic Agents/administration & dosage[MESH]
  • |Host-Pathogen Interactions[MESH]
  • |Humans[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*blood/diagnosis/drug therapy/virology[MESH]
  • |Prospective Studies[MESH]
  • |Treatment Outcome[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1747 7.18 2020